Bright future for tech stocks in post-Covid world

ON NOV 9, 2020, Pfizer announced a wonderful development for mankind. Trial results from the pharmaceutical giant's Covid-19 vaccine candidate, developed together with Bio NTech, showed that it could be 90 per cent effective in preventing infection.

A week later, Moderna revealed that its Covid-19 vaccine candidate was 94.5 per cent effective in trials. This was followed by an update from Pfizer a few days later that its vaccine candidate was actually 95 per cent effective .

Covid-19 is still a serious global health threat. Pfizer and Moderna's vaccines have yet to pass regulatory approvals at the time of writing (Nov19, 2020). Both companies have said too that they can supply their respective vaccines at scale only in 2021. Pfizer's vaccine candidate also poses a significant logistical challenge since it needs to be transported and stored at an extremely cold temperature of minus 70 degrees celsius .